Merck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media
- Company to present 54 abstracts across its MS portfolio -MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib
- New long-term data and real-world evidence further characterise efficacy and safety of MAVENCLAD®
- New MAVENCLAD® and Rebif® safety data to be shared demonstrating no increased risk of respiratory viral infections
Merck, a leading science and technology company, today announced it will!-->…